Vanda Pharmaceuticals | VNDA - Assets


Vanda Pharmaceuticals reported $488.95M in Assets for its fiscal quarter ending in December of 2025.





Assets Change Date
Acadia Pharmaceuticals USD 1.56B 233.42M Dec/2025
Agios Pharmaceuticals USD 1.18B 112.24M Mar/2026
Akebia Therapeutics USD 376.56M 12.41M Dec/2025
Alnylam Pharmaceuticals USD 5.13B 163.22M Mar/2026
Anika Therapeutics USD 179.39M 10.88M Mar/2026
Arrowhead Research USD 1.6B 218.89M Dec/2025
AstraZeneca USD 114.02B 59M Mar/2026
Bristol-Myers Squibb USD 86.48B 3.56B Mar/2026
Eli Lilly USD 116.58B 4.1B Mar/2026
Enanta Pharmaceuticals USD 329.5M 48.77M Dec/2025
Esperion Therapeutics USD 465.89M 101.87M Dec/2025
Halozyme Therapeutics USD 2.53B 304.09M Dec/2025
Heron Therapeutics USD 255.88M 6.93M Dec/2025
Insmed USD 2.26B 96.18M Dec/2025
J&J USD 200.89B 1.68B Mar/2026
Lexicon Pharmaceuticals USD 184.99M 20.94M Dec/2025
Ligand Pharmaceuticals USD 1.56B 83.86M Dec/2025
Merck USD 128.68B 8.18B Mar/2026
Minerva Neurosciences USD 97.97M 69.88M Dec/2025
Moderna USD 11.49B 850M Mar/2026
Novartis USD 110.95B 3.66B Dec/2025
Pfizer USD 207.62B 542M Mar/2026
PTC Therapeutics USD 2.9B 255.07M Dec/2025
Puma Biotechnology USD 202.86M 7.95M Sep/2025
Sangamo BioSciences USD 97.56M 11.39M Jun/2025
Sanofi EUR 128.02B 1.22B Mar/2026
Takeda JPY 15.41T 938.47B Dec/2025
Teva Pharmaceutical Industries USD 40.04B 708M Mar/2026
Ultragenyx Pharmaceutical USD 1.53B 341.56M Dec/2025
Vanda Pharmaceuticals USD 488.95M 112.19M Dec/2025
Veracyte USD 1.41B 38.23M Dec/2025